colistimethate sodium has been researched along with Disease Exacerbation in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cogen, JD; Goss, CH; Nichols, DP; Nick, JA; Nick, SE; Russell, R; Saavedra, MT; Somayaji, R; Taylor-Cousar, JL | 1 |
| Cantrell, A; Carroll, C; Harnan, S; Mildred, M; Tappenden, P; Uttley, L | 1 |
| Brownlee, K; Cantrell, A; Harnan, S; Tappenden, P; Taylor, C; Uttley, L; Walshaw, M | 1 |
| Angyalosi, G; Balp, MM; Capkun-Niggli, G; Doering, G; Higashi, K; Jansen, JP; Littlewood, KJ; Tiddens, HA | 1 |
| Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT | 1 |
3 review(s) available for colistimethate sodium and Disease Exacerbation
| Article | Year |
|---|---|
Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
Topics: Administration, Inhalation; Child; Colistin; Cost-Benefit Analysis; Cystic Fibrosis; Disease Progression; Humans; Outcome Assessment, Health Care; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Therapeutic Equivalency; Tobramycin; United Kingdom | 2013 |
Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Disease Progression; Dry Powder Inhalers; Evidence-Based Medicine; Forced Expiratory Volume; Humans; Lung; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Research Design; Time Factors; Tobramycin; Treatment Outcome | 2013 |
A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Bacterial Load; Bayes Theorem; Biological Availability; Chronic Disease; Colistin; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Information Services; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Tobramycin; Treatment Outcome | 2012 |
2 other study(ies) available for colistimethate sodium and Disease Exacerbation
| Article | Year |
|---|---|
Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
Topics: Administration, Inhalation; Administration, Intravenous; Adult; Anti-Bacterial Agents; Azithromycin; Colistin; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Logistic Models; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin; Young Adult | 2019 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Disease Progression; Female; Humans; Male; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2013 |